Application of UA-MHC HLA-A*1101/VVVGADGVGK KRAS G12D tetramer-PE labeling in the detection of antigen-specific T cells

1. Research Background of Tumor Driver Gene Mutations as Immunotherapy Targets

The KRAS gene is one of the most frequently mutated oncogenes in tumors, with the G12D mutation widely present in various malignancies such as pancreatic cancer, colorectal cancer, and lung cancer. The neoantigen peptide derived from this mutation site provides an ideal target for tumor immunotherapy. Accurately identifying and quantitatively analyzing neoantigen-specific CD8+ T cells targeting the KRAS G12D mutation is crucial for elucidating anti-tumor immune mechanisms and evaluating immunotherapy efficacy. The establishment of major histocompatibility complex (MHC) tetramer technology provides a key technical means for directly visualizing and quantitatively analyzing this low-frequency but highly specific T cell population.

2. Core Principle of MHC Tetramer Technology

The principle of MHC tetramer technology is based on the specific recognition between T cell receptors (TCR) and MHC-antigen peptide complexes. Biotinylated monomeric MHC-antigen peptide complexes are mixed with fluorescently labeled streptavidin at an optimized ratio. The four biotin-binding sites of streptavidin can simultaneously bind four MHC monomers, forming a stable tetramer structure. This tetramer structure significantly enhances the binding affinity to antigen-specific TCRs, enabling stable labeling of antigen-specific CD8+ T cells. Combined with flow cytometry, labeled cells can be precisely characterized and quantitatively analyzed. Additionally, by co-staining with other surface markers, the phenotypic characteristics, differentiation states, and functional subsets of antigen-specific T cells can be further explored. This technology has been widely used to detect neoantigen-specific T cells in human peripheral blood and tumor tissues.

3. Construction and Characteristics of HLA-A*1101/VVVGADGVGK KRAS G12D Tetramer

The HLA-A*1101/VVVGADGVGK KRAS G12D tetramer is a specific detection tool assembled from human HLA-A*1101 MHC class I molecules and the VVVGADGVGK peptide derived from the KRAS G12D mutation. This tetramer is labeled with PE fluorescence, offering high sensitivity, high specificity, and excellent photostability. PE fluorophore has high quantum yield and strong resistance to photobleaching, making it suitable for multicolor flow cytometry analysis of human samples. The KRAS G12D mutation is a common driver gene mutation in tumors, and the neoantigen peptide encoded by the altered amino acid can be presented by HLA molecules, eliciting specific T cell immune responses. This tetramer can specifically recognize CD8+ T cells with TCRs targeting the KRAS G12D mutation peptide, making it widely applicable for detecting and analyzing mutation-specific T cells in human tumor immunology research.

4. Applications in Tumor Immune Monitoring

The HLA-A*1101/VVVGADGVGK KRAS G12D tetramer plays a critical role in monitoring the immune status of tumor patients. Using this tetramer, researchers can detect the frequency of KRAS G12D-specific CD8+ T cells in peripheral blood mononuclear cells (PBMCs) and analyze their correlation with tumor burden, disease stage, and prognosis. In tumor tissues, this tetramer can be used to detect the proportion and distribution of mutation-specific T cells among tumor-infiltrating lymphocytes (TILs). By co-staining with immune inhibitory molecules such as PD-1, LAG-3, and TIGIT, the functional exhaustion status of neoantigen-specific T cells in the tumor microenvironment can be assessed. Such studies provide important data for understanding tumor immune editing mechanisms and patient immune stratification.

5. Applications in Immunotherapy Efficacy Evaluation

Immune checkpoint blockade therapy and adoptive T cell therapy continue to make progress in the treatment of solid tumors. The HLA-A*1101/VVVGADGVGK KRAS G12D tetramer provides a direct detection tool for evaluating immunotherapy strategies targeting driver gene mutations. In patients receiving immunotherapy, this tetramer can be used to dynamically monitor changes in the frequency of KRAS G12D-specific CD8+ T cells, assessing the extent of mutation-specific T cell expansion induced by treatment. By co-staining with activation markers such as CD38, HLA-DR, and Ki-67, the in vivo activation state and proliferative activity of antigen-specific T cells can be evaluated. The correlation analysis of these parameter changes with clinical efficacy provides key data support for understanding treatment mechanisms and optimizing therapeutic strategies.

6. Applications in Neoantigen Vaccine Development

Neoantigen vaccines targeting driver gene mutations represent a cutting-edge direction in tumor immunotherapy. The HLA-A*1101/VVVGADGVGK KRAS G12D tetramer provides a standardized tool for evaluating the immunogenicity of neoantigen vaccines. After vaccination with candidate vaccines containing the KRAS G12D mutation peptide, this tetramer can be used to detect the frequency of mutation-specific CD8+ T cells in peripheral blood, assessing the strength and durability of the T cell response induced by the vaccine. By comparing the neoantigen-specific T cell responses induced by different vaccine vectors, adjuvants, and immunization regimens, the optimal immunization strategy can be selected. This method offers high sensitivity, enabling the detection of low-frequency mutation-specific T cells, and is suitable for immune monitoring in early-stage clinical studies.

7. Applications in T Cell Receptor-Engineered T Cell Therapy

T cell receptor-engineered T cell (TCR-T) therapy targeting the KRAS G12D mutation is currently under clinical development. The HLA-A*1101/VVVGADGVGK KRAS G12D tetramer plays multiple roles in the research and application of such therapies. During the quality control of TCR-T cells, this tetramer can be used to assess the recognition capability of engineered T cells for the mutation peptide and the functional receptor expression level. In post-treatment immune monitoring, this tetramer can be used to track the survival, expansion, and homing dynamics of infused T cells in patients, evaluating the in vivo persistence and anti-tumor activity of adoptive T cells. This technology provides an essential quality control and monitoring tool for mutation-targeted adoptive T cell therapy.

8. Which Manufacturers Provide UA-MHC HLA-A*1101/VVVGADGVGK KRAS G12D Tetramer-PE Labeling?

Nanjing UA-Bio Technology Co., Ltd. (UA-Bio) has independently developed the "UA-MHC HLA-A*1101/VVVGADGVGK KRAS G12D Tetramer-PE Labelled", a high-performance MHC tetramer reagent specifically designed for the identification and sorting of antigen-specific CD8+ T cells. This product is based on the complex of human HLA-A*1101 MHC class I molecules and the VVVGADGVGK antigen peptide derived from the KRAS G12D mutation, labeled with PE fluorescence. It is designed to accurately and efficiently identify and quantify KRAS G12D mutation-specific CD8+ T cells, providing a stable and reliable standardized tool for tumor immunotherapy, targeted drug development, immune monitoring, and other fields.

Nanjing UA-Bio Technology Co., Ltd. is always committed to providing cutting-edge, high-quality core reagents and tools for the fields of immunology, cell therapy, and innovative drug development. For detailed technical parameters, validation data, or specific application inquiries regarding the "UA-MHC HLA-A*1101/VVVGADGVGK KRAS G12D Tetramer-PE Labelled" (Catalog No.: UA089044), please feel free to contact us.